Efficacy observation of DA-EPOCH-R protocol for patients with B-cell non-Hodgkin lymphoma
10.3760/cma.j.issn.1009-9921.2017.04.006
- VernacularTitle:DA-EPOCH-R方案治疗B细胞非霍奇金淋巴瘤效果观察
- Author:
Wei WU
;
Jianhua SHAO
;
Daqi LI
;
Xuebin DONG
;
Ping CHEN
;
Hongyu ZHAO
;
Linping GU
;
Lin SUN
;
Jie XIE
- Keywords:
Lymphoma;
non-Hodgkin;
DA-EPOCH-R protocol;
Biphenotypic lymphoma
- From:
Journal of Leukemia & Lymphoma
2017;26(4):217-220
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of DA-EPOCH-R protocol for patients with B-cell non-hodgkin lymphoma (NHL). Methods 43 patients with B-cell NHL received DA-EPOCH-R protocol, and their efficacy and adverse reactions were analyzed. Results 43 patients received a total of 203 cycles of chemotherapy and the median chemotherapy cycle was 6 (2ˉ8 cycles). 32 patients (74.4%) achieved complete remission (CR) after 2ˉ4 cycles of chemotherapy. A further analysis found that age ≤60 years and>60 years, stageⅠ/Ⅱand stageⅢ/Ⅳ, germinal center B-cell (GCB), non-GCB, double expression lymphoma (DEL) and non-DEL patients had no significant differences (P> 0.05). With a median follow-up of 40 months (9ˉ62 mouths), the overall survival (OS) rate of 1-year and 3-year was 97.6 % and 92.8 % respectively. The major toxicity of DA-EPOCH-R protocol was hematologic toxicity. Other toxicities were mild, and no treatment-related deaths occurred. At the end of follow-up, no secondary tumors were found. Conclusions DA-EPOCH-R protocol is an effective and safe protocol for patients with NHL. The result shows that the curative effect of patients in stageⅢandⅣis similar to the patients in stageⅠandⅡ.
